Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Medical Hypotheses, 4(76), p. 467-470, 2011

DOI: 10.1016/j.mehy.2010.11.022

Links

Tools

Export citation

Search in Google Scholar

The normobaric oxygen paradox: a novel way to administer oxygen as an adjuvant treatment for cancer?

Journal article published in 2011 by David De Bels, Francis Corazza, Peter Germonpré, Costantino Balestra ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The "normobaric oxygen paradox" is a dual mechanism by which oxygen regulates the expression of the Hypoxia Inducible Factor 1 alpha (HIF-1α). The HIF-1α-depending gene regulation is responsible for many different genetic expressions including EPO and VEGF that are usually expressed in parallel. First, VEGF under-expression could decrease tumor angiogenesis leading to a decrease in tumor growth or even apoptosis of cancer cells. Second, induction of EPO-expression can provide cytoprotection. Altogether, this could be deleterious for cancer cells while helping non-malignant cells (at least neural and cardiac) cells to be protected from the side effects of chemotherapy. Eventually, HIF induction could boost immune response by inflammatory cells, increasing their antitumor activity. ; Journal Article ; info:eu-repo/semantics/published